The post Coinbase’s Dogecoin Collateral News Fails to Spark Price Recovery appeared on BitcoinEthereumNews.com. According to our recent report, Coinbase has addedThe post Coinbase’s Dogecoin Collateral News Fails to Spark Price Recovery appeared on BitcoinEthereumNews.com. According to our recent report, Coinbase has added

Coinbase’s Dogecoin Collateral News Fails to Spark Price Recovery

According to our recent report, Coinbase has added Dogecoin, XRP, Cardano, and Litecoin as collateral options for its crypto-backed loan product. Despite the significance of the update, Dogecoin prices have shown no meaningful recovery. The meme coin continues to trade under pressure, reflecting broader market weakness.

Qualified U.S. users, excluding those in New York, can now borrow up to $100,000 in USDC stablecoin using these assets on the Base network via Morpho. The feature eliminates the need to sell holdings, offering crypto owners greater financial flexibility. Previously, Coinbase’s loan product was limited to Bitcoin and Ethereum only.

The expansion marks a notable shift in how retail investors can leverage altcoin holdings. Yet market participants appear unmoved. Dogecoin traded at $0.09739 at the time of writing, down 0.94% in the last 24 hours. Despite gaining 6.48% over the last 7 days, the memecoin is still 21.3% down over the last 30 days.

Dogecoin Struggles Despite Positive Developments

The Coinbase announcement arrived during a difficult stretch for Dogecoin. The token reached a high of $0.1175 on Sunday following a three-day rally. Profit-taking quickly followed. Multiple attempts to reclaim $0.10 between February 16 and 18 failed. Sellers maintained control throughout the week, and Dogecoin could not breach the $0.10 level during Thursday’s session.

Trading volume dropped 2.19% in 24 hours to $860 million. Derivatives market volume fell 2.08% to $1.81 billion. Open interest declined 5% to $1.8 billion. These figures point to fading conviction among both spot and derivatives traders.

Glassnode data adds further context. The 90-day simple moving average tracking open interest changes across top crypto assets has remained negative since October 2025. This sustained decline suggests institutional and retail appetite for Dogecoin exposure has been shrinking for months.

The Coinbase update, while practically meaningful, has not changed the technical or sentiment picture. Traders appear focused on macro headwinds rather than platform-level developments.

Macro Pressure Weighs on the Broader Crypto Market

Dogecoin’s decline is not happening in isolation. The broader crypto market sold off sharply despite gains on Asian and U.S. equity markets. A firmer U.S. dollar added pressure across digital assets. Federal Reserve minutes released this week signaled no urgency to cut interest rates. Policymakers also left open the possibility of further rate hikes, dampening risk appetite.

The Crypto Fear and Greed Index sits at 11, deep in extreme fear territory. A total of $214 million in crypto positions were liquidated in the last 24 hours, according to CoinGlass. The liquidation data reflect a market where overleveraged positions are being forcibly closed as prices fall.

When macro conditions dominate sentiment, individual asset announcements rarely move markets. Coinbase’s expansion of collateral options is a structural improvement. It does not, however, address the external forces currently driving prices lower.

Source: https://coinpaper.com/14769/dogecoin-price-stays-flat-despite-coinbase-collateral-update

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0008691
$0.0008691$0.0008691
+27.00%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03